Joseph J. LaRosa Net Worth

The estimated Net Worth of Joseph J Larosa is at least $60.1 Million dollars as of 11 July 2024. Mr Larosa owns over 1,866 units of Regeneron Pharmaceuticals stock worth over $43,303,189 and over the last 13 years he sold REGN stock worth over $15,029,211. In addition, he makes $1,748,110 as Exec. VP and Gen. Counsel & Sec. at Regeneron Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr LaRosa REGN stock SEC Form 4 insiders trading

Mr has made over 23 trades of the Regeneron Pharmaceuticals stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 1,866 units of REGN stock worth $2,031,981 on 11 July 2024.

The largest trade he's ever made was exercising 34,000 units of Regeneron Pharmaceuticals stock on 3 January 2024 worth over $13,588,440. On average, Mr trades about 5,885 units every 81 days since 2011. As of 11 July 2024 he still owns at least 37,937 units of Regeneron Pharmaceuticals stock.

You can see the complete history of Mr Larosa stock trades at the bottom of the page.

Mr. Joseph J. LaRosa biography

Joseph J. LaRosa is the Exec. VP, Gen. Counsel & Sec. at Regeneron Pharmaceuticals.

What is the salary of Mr LaRosa?

As the Exec. VP and Gen. Counsel & Sec. of Regeneron Pharmaceuticals, the total compensation of Mr LaRosa at Regeneron Pharmaceuticals is $1,748,110. There are 13 executives at Regeneron Pharmaceuticals getting paid more, with P. Roy Vagelos having the highest compensation of $22,304,300.

How old is Mr LaRosa?

Mr LaRosa is 62, he's been the Exec. VP and Gen. Counsel & Sec. of Regeneron Pharmaceuticals since . There are 9 older and 14 younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals, Inc. is P. Roy Vagelos, 90, who is the Chairman of the Board, Director.

Insiders trading at Regeneron Pharmaceuticals

Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis, and Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.

What does Regeneron Pharmaceuticals do?

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.

Complete history of Mr Larosa stock trades at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals executives and stock owners

Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include:

• P. Roy Vagelos,
  Chairman of the Board, Director
• Leonard Schleifer,
  President, Chief Executive Officer, Director
• George Yancopoulos,
  President, Chief Scientific Officer, Director
• Marion McCourt,
  Senior Vice President - Commercial
• Andrew Murphy,
  Executive Vice President - Research
• Neil Stahl,
  Executive Vice President - Research and Development
• Robert Landry,
  Chief Financial Officer, Executive Vice President - Finance
• Daniel Van Plew,
  Executive Vice President, General Manager - Industrial Operations and Product Supply
• Dr. George D. Yancopoulos M.D., Ph.D.,
  Scientific Founder, Pres, Chief Scientific Officer & Director
• Dr. Leonard S. Schleifer M.D., Ph.D.,
  Founder, Pres, CEO & Director
• Dr. George D. Yancopoulos,
  Scientific Founder, Pres, Chief Scientific Officer & Director
• Robert E. Landry Jr.,
  Exec. VP of Fin. & CFO
• Daniel P. Van Plew,
  Exec. VP and GM of Industrial Operations & Product Supply
• Joseph J. LaRosa,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Andrew J. Murphy,
  Exec. VP of Research
• Arthur Ryan,
  Independent Director
• George Sing,
  Independent Director
• Christine Poon,
  Independent Director
• Michael Brown,
  Independent Director
• Huda Zoghbi,
  Independent Director
• Joseph Goldstein,
  Independent Director
• Bonnie Bassler,
  Independent Director
• N. Anthony Coles,
  Independent Director
• Marc Tessier-Lavigne,
  Independent Director
• Christopher Fenimore,
  Vice President, Controller
• Joseph LaRosa,
  Executive Vice President, General Counsel, Secretary
• Justin Holko,
  VP of Investor Relations
• Bob McCowan,
  Sr. VP of IT & Chief Information Officer
• Gerald Underwood,
  Sr. VP of Technical Operations
• Christopher R. Fenimore,
  Sr. VP, Head of Accounting & Controller
• Patrice Gilooly,
  Sr. VP of Quality Assurance & Operations
• Charles A Baker,
  Director
• Michael S Aberman,
  SVP Strategy Investor Relation
• Sanofi,
  
• Robert J Terifay,
  EVP Commercial
• Alfred G Gilman,
  Director
• Robert Alexander Ingram,
  Director
• Eric M Shooter,
  Director
• Murray A Goldberg,
  SVP Administration & Asst Secr
• Stuart Kolinski,
  SVP General Counsel and Secret
• Amerique Du Nord S.N.C. San...,
  
• Peter Dworkin,
  VP Investor Relations & Commun
• Randall Rupp,
  SVP, Manufuring Operations
• Pharma Ag Novartis,
  10% owner
• Hans Peter Guler,
  VP Clinical Programs
• William Roberts,
  VP Reg Dev & Med Safety
• Peter Powchik,
  SVP Clinical Development & Reg
• Douglas S Mc Corkle,
  VP Controller and Asst Treasur
• Craig B. Thompson,
  Director
• Kathryn Guarini,
  Director
• David P Schenkein,
  Director
• Jason Pitofsky,
  VP Controller